Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

nties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

For Genta Incorporated

Tara Spiess

TS Communications Group, LLC

(908) 286-3980

info@genta.com

Genta Incorporated

Selected Condensed Consolidated Financial Data

(In thousands, except per share data)

(Unaudited)

Three Months Ended Six Months Ended

June 30 June 30

2007 2006 2007 2006

Product sales - net $105 $379 $199 $446

Cost of goods sold 26 22 48 38

Gross margin 79 357 151 408

Operating expenses:

Research and development 4,099 8,637 7,481 13,387

Selling, general and

administrative 4,735 6,716 8,787 12,173

Reduction in liability for

settlement of litigation (240) - (1,800) -

Total operating expenses 8,594 15,353 14,468 25,560

Other income 280 354 478 614

Net loss $(8,235) $(14,642) $(13,839) $(24,538)

Net loss per basic and diluted

share $(0.27) $(0.66) $(0.48) $(1.17)

Shares used in computing basic and

diluted net loss per share

(adjusted for 1-for-6 reverse

stock split on July 13, 2007) 30,621 22,278 28,604 20,995

Selected Condensed Consolidated Balance Sheet Data


'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:World first: researchers develop completely automated anesthesia system 2Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care 2Health News:New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care 3Health News:New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care 4Health News:Napping Habits Tied to Sleep Disorders 2Health News:Home Monitoring Program Improves Outcomes for Heart Patients 2